AstraZeneca's Imfinzi Combo Approved In US For Muscle-Invasive Bladder Cancer Treatment

(RTTNews) - British drug major AstraZeneca Plc.'s (AZN, AZN.L) Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the bladder) has been approved in th https://www.nasdaq.com/articles/astrazenecas-imfinzi-combo-approved-us-muscle-invasive-bladder-cancer-treatment